These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
741 related articles for article (PubMed ID: 30573057)
1. Outcomes Among Diabetic Patients Undergoing Percutaneous Coronary Intervention With Contemporary Drug-Eluting Stents: Analysis From the BIONICS Randomized Trial. Konigstein M; Ben-Yehuda O; Smits PC; Love MP; Banai S; Perlman GY; Golomb M; Ozan MO; Liu M; Leon MB; Stone GW; Kandzari DE JACC Cardiovasc Interv; 2018 Dec; 11(24):2467-2476. PubMed ID: 30573057 [TBL] [Abstract][Full Text] [Related]
2. Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 2-Year Clinical Outcomes From the BIONICS and NIREUS Trials. Konigstein M; Smits PC; Love MP; Ben-Yehuda O; Ozan MO; Liu M; Perlman GY; Leon MB; Stone GW; Kandzari DE JACC Cardiovasc Interv; 2020 Jan; 13(1):86-93. PubMed ID: 31918946 [TBL] [Abstract][Full Text] [Related]
3. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial. Zocca P; Kok MM; Tandjung K; Danse PW; Jessurun GAJ; Hautvast RWM; van Houwelingen KG; Stoel MG; Schramm AR; Tjon Joe Gin RM; de Man FHAF; Hartmann M; Louwerenburg JHW; Linssen GCM; Löwik MM; Doggen CJM; von Birgelen C JACC Cardiovasc Interv; 2018 Mar; 11(5):462-469. PubMed ID: 29519378 [TBL] [Abstract][Full Text] [Related]
4. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202 [TBL] [Abstract][Full Text] [Related]
5. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents. Kandzari DE; Leon MB; Meredith I; Fajadet J; Wijns W; Mauri L JACC Cardiovasc Interv; 2013 May; 6(5):504-12. PubMed ID: 23602459 [TBL] [Abstract][Full Text] [Related]
6. A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial). Maeng M; Baranauskas A; Christiansen EH; Kaltoft A; Holm NR; Krusell LR; Ravkilde J; Tilsted HH; Thayssen P; Jensen LO Catheter Cardiovasc Interv; 2015 Dec; 86(7):1161-7. PubMed ID: 25640050 [TBL] [Abstract][Full Text] [Related]
7. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial. Raungaard B; Christiansen EH; Bøtker HE; Hansen HS; Ravkilde J; Thuesen L; Aarøe J; Villadsen AB; Terkelsen CJ; Krusell LR; Maeng M; Kristensen SD; Veien KT; Hansen KN; Junker A; Madsen M; Andersen SL; Jensen SE; Jensen LO; JACC Cardiovasc Interv; 2017 Feb; 10(3):255-264. PubMed ID: 28109874 [TBL] [Abstract][Full Text] [Related]
8. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial. Harada Y; Colleran R; Kufner S; Giacoppo D; Rheude T; Michel J; Cassese S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA; Cardiovasc Diabetol; 2016 Sep; 15(1):124. PubMed ID: 27586678 [TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859 [TBL] [Abstract][Full Text] [Related]
11. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698 [TBL] [Abstract][Full Text] [Related]
12. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial. Jang SJ; Park DW; Kim WJ; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ Catheter Cardiovasc Interv; 2013 Jun; 81(7):1106-14. PubMed ID: 22899589 [TBL] [Abstract][Full Text] [Related]
13. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. Kirtane AJ; Patel R; O'Shaughnessy C; Overlie P; McLaurin B; Solomon S; Mauri L; Fitzgerald P; Popma JJ; Kandzari DE; Leon MB JACC Cardiovasc Interv; 2009 Oct; 2(10):967-76. PubMed ID: 19850257 [TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of complex real-world diabetic patients treated with amphilimus sirolimus-eluting stents or zotarolimus-eluting stents: A single-center registry. Rozemeijer R; Benedetto D; Kraaijeveld AO; Voskuil M; Stein M; Timmers L; Rittersma SZ; Agostoni P; Doevendans PA; Stella PR Cardiovasc Revasc Med; 2018 Jul; 19(5 Pt A):521-525. PubMed ID: 29137966 [TBL] [Abstract][Full Text] [Related]
15. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of Zotarolimus- vs. Paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries: five-year results from the ZOMAXX I trial. Chevalier B; Dimario C; Neumann FJ; Cutlip DE; Williams DO; Ormiston J; Grube E; Whitbourn R; Coe J; Schwartz LB; Catheter Cardiovasc Interv; 2013 Dec; 82(7):1039-47. PubMed ID: 23592567 [TBL] [Abstract][Full Text] [Related]
16. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease. Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A; JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416 [TBL] [Abstract][Full Text] [Related]
17. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus. Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802 [TBL] [Abstract][Full Text] [Related]
18. Comparison of long-term clinical outcomes in multivessel coronary artery disease patients treated either with bioresoarbable polymer sirolimus-eluting stent or permanent polymer everolimus-eluting stent: 5-year results of the CENTURY II randomized clinical trial. Iñiguez A; Chevalier B; Richardt G; Neylon A; Jiménez VA; Kornowski R; Carrie D; Moreno R; Barbato E; Serra-Peñaranda A; Guiducci V; Valdés-Chávarri M; Yajima J; Wijns W; Saito S; Catheter Cardiovasc Interv; 2020 Feb; 95(2):175-184. PubMed ID: 31033154 [TBL] [Abstract][Full Text] [Related]
19. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease). Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C; JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444 [TBL] [Abstract][Full Text] [Related]
20. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]